Kiniksa Pharmaceuticals International, plc $KNSA Stake Trimmed by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 5.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 267,274 shares of the company’s stock after selling 15,014 shares during the quarter. Fisher Asset Management LLC owned approximately 0.35% of Kiniksa Pharmaceuticals International worth $11,025,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth about $31,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Kiniksa Pharmaceuticals International in the 4th quarter worth about $41,000. Quantbot Technologies LP purchased a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth about $43,000. Finally, Quarry LP purchased a new position in Kiniksa Pharmaceuticals International in the 3rd quarter worth about $44,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on KNSA shares. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 29th. Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, May 6th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Trading Down 1.9%

Shares of NASDAQ KNSA opened at $51.84 on Thursday. Kiniksa Pharmaceuticals International, plc has a one year low of $26.27 and a one year high of $59.87. The firm has a market capitalization of $3.99 billion, a PE ratio of 57.60 and a beta of 0.17. The business has a 50-day moving average price of $49.79 and a two-hundred day moving average price of $45.26.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same period last year, the company posted $0.11 EPS. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CAO Michael R. Megna sold 6,625 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $46.69, for a total transaction of $309,321.25. Following the completion of the sale, the chief accounting officer directly owned 27,418 shares in the company, valued at $1,280,146.42. The trade was a 19.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the sale, the chief executive officer owned 48,565 shares of the company’s stock, valued at approximately $2,623,481.30. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 653,301 shares of company stock worth $34,046,073 over the last quarter. Insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.